Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Moschini M, Soria F, Susani M, Korn S, Briganti A, Rouprêt M, et al. Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. Bladder Cancer. 2017;3(3):161-169.

Tran JN, Ash KJ, Seshan SV, Kelly KM. Clinicopathological Features of Cardiac Glycolipid Storage Disease in an Adult Pug. J Comp Pathol. 2017;156(2-3):235-239.

Petrova-Drus K, Hasserjian R, Pozdnyakova O, Dal Cin P, Mathew S, Margolskee E, et al. Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome. Leuk Lymphoma. 2017;58(3):569-577.

Liang K, Liu F, Fan J, Sun D, Liu C, Lyon CJ, et al. Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring. Nat Biomed Eng. 2017;1.

Nguyen GH, Olson LC, Magro CM. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome. Ann Diagn Pathol. 2017;28:54-59.

Gullett JC, Westblade LF, Green DA, Whittier S, Burd EM. The Brief Case: Too Beta To Be a "B". J Clin Microbiol. 2017;55(6):1604-1607.

S Wu P, Cooper BT, Bu F, Bowman CJ, J Killian K, Serrano J, et al. DNA Methylation-Based Classifier for Accurate Molecular Diagnosis of Bone Sarcomas. JCO Precis Oncol. 2017;2017.

Magro CM, Davis TL, Kurtzman DJ. Epidermotropic marginal zone lymphoma: An uncommon cutaneous B-cell lymphoma responsive to rituximab. JAAD Case Rep. 2017;3(6):474-476.

Levitan D, Harper AE, Sun Y, Carniello JV, Momeni A, Kagan J, et al. Do Serum Creatinine Levels Show Clinically Significant Fluctuations on Serial Determinations on the Siemens Advia 1800 Analyzer? J Clin Lab Anal. 2017;31(1).

Kabraji S, Solé X, Huang Y, Bango C, Bowden M, Bardia A, et al. AKT1 quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer. Breast Cancer Res. 2017;19(1):88.